We recently announced a list of 11 Healthcare stock that performs best to buy now. In this article, we're going to look at where Soleno Therapeutics, Inc. (NASDAQ:Slump) stands against other healthcare stocks that perform best to buy now.
On April 15, CNBC reported that an executive order focusing on the healthcare of President Trump had brought victory to the sector. Trump directed his health department to work with Congress to overhaul a law that allows Medicare to discuss prescription drug prices. The announcement seeks to bring a change that the pharmaceutical company has lobbied for. As the negotiation process is included in legislation, Trump's executive order cannot implement the change itself. However, he directs the Health and Human Services Secretary Robert F. Kennedy Jr to join and change hands with Congress.
CNBC reported that drug makers have been working to delay the competence to small molecule drugs to be available for four -year price negotiations. This typically includes pills and most medicines. This goes hand in hand with the waiting 13 years until more complex biotechnology drugs are eligible for Medicare price negotiations.
Trump's wide executive order also focuses on cutting healthcare costs. It comes a day after the administration established a national security report on the pharma industry. CNBC called the report “a precursor to sector-specific tariffs.”
Medicare negotiation powers have been the subject of contention, as drug makers have chosen that they would prevent innovation and have gathered against the time frame for negotiation competence for most drugs. The law now allows the government to discuss drug prices with no competition, which includes complex biological or biological medicines after 13 years on the market, but 9 years to be administered as capsules and pills.
Although they did not provide specific details, White House officials told reporters that other changes to the negotiation process would result in more savings than those reached during the first round under the Biden Administration. Although the Biden Administration negotiated price cuts as steep as 79% for the first ten most expensive drugs to the Medicare program, Trump's administration would negotiate prices for the following 15 medicines. This includes Pfizer Ibrance and Xdandi cancer drugs, as well as Novo Nordisk's sweeping diabetes and Ozempic and Wegovy weight loss treatments.
We used Finviz to screen healthcare stocks and select the best performers based on their performance to date (YTD), on May 9, 2025. We also included the number of hedgerow reservoir holders for each stock on CH4 2024. The list is sorted in the ascending order of the performance to date.
Why are we worried about what hedge funds are doing? The reason is simple: our research has shown that we can outperform the market by imitating the main stock options of the best hedge funds. Our quarterly newsletter strategy selects 14 small cap stocks and a large cap every quarter and has returned 275% since May 2014, beating its 150 percentage benchmarkSee more details here).
Why went Soleno Therapeutics Inc. (Slno) up last week?
Board room of a clinical phase biopharmaceutical company, emphasizing the importance of making decisions for the development of an oral tablet lead candidate once daily.
YTD Performance: 70.81%
Number of Hedgerow Fund Holders: 39
Soleno Therapeutics, Inc. (NASDAQ: SLNO) third on our list of healthcare stocks that are currently performing to invest in. It is a clinical stage biopharmaceutical company that develops and commercializes new therapeutics to treat rare diseases. The company focuses on treating neurodegeneration and metabolic disorders. His lead candidate, controlled release of Colin Diazoxide (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).
On April 14, Soleno Therapeutics, Inc. (NASDAQ: SLNO) that its Vykat XR extended release tablets are now commercially available in the United States for the treatment of Prader-Willi syndrome, approved by the US Food and Drug Administration on March 26, 2025 A company is called developed, developed exors, developed, developed, developed, developed, to be part of a company. the drug.
On April 15, HC Wainwright analyst Ram Selvaraju repeated a purchase score on Soleno Therapeutics, Inc. (NASDAQ: SLNO) and set a price target of $ 100.00.
On the whole, slno 3rd ranks On our list of the best performing healthcare stocks to buy now. While we recognize the potential for Slno as an investment, our conviction lies in the belief that some AI stocks are more promised for achieving higher gains and doing so within a shorter time frame. There has been AI stock that has risen since the beginning of 2025, while popular AI stocks lose about 25%. If you are looking for AI stock that is more promising than slno but trading at less than 5 times its earnings, check out our report for this Cheapest AI Stock.
